CARLOS GOMEZ: Open Payments
NPI 1407466774 · PEMBROKE PINES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,855 in 79 payments from 13 companies in 2025. Trend: 2023 $1,565 · 2024 $1,133 · 2025 $1,855
Food & beverage: $1,855
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $236 |
| Neurocrine BioSciences, Inc. | 8 | $210 |
| Alkermes, Inc. | 10 | $209 |
| Otsuka America Pharmaceutical, Inc. | 9 | $206 |
| Teva Pharmaceuticals USA, Inc. | 10 | $188 |
| ABBVIE INC. | 10 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $170 |
| Corium, LLC | 5 | $132 |
| E.R. Squibb & Sons, L.L.C. | 4 | $114 |
| Lundbeck LLC | 3 | $81 |
Products named: REXULTI, HETLIOZ, INGREZZA, AUSTEDO XR, VRAYLAR, CAPLYTA, ARISTADA, Azstarys.
Industry payments across FL — which companies pay providers there.
